FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Antagonist topics
Antagonist
Recurrence
Proliferative Disorder
Proliferative
Antibodies
Progesterone
Dicyclomine
Scopolamine
Extracellular
Pharmaceutically Acceptable Salt
Metalloprotein
Nucleic Acids
Polynucleotide
Nucleic Acid
Monoclonal

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Antagonist patents



      
           
This page is updated frequently with new Antagonist-related patent applications. Subscribe to the Antagonist RSS feed to automatically get the update: related Antagonist RSS feeds. RSS updates for this page: Antagonist RSS RSS


Date/App# patent app List of recent Antagonist-related patents
09/25/14
20140288185
 Nicotinic receptor non-competitive modulators patent thumbnailnew patent Nicotinic receptor non-competitive modulators
The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for their synthesis, methods for use, and their pharmaceutical compositions.. .
09/25/14
20140288169
 Nicotinic receptor non-competitive antagonists patent thumbnailnew patent Nicotinic receptor non-competitive antagonists
The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for their synthesis, methods for their use, and their pharmaceutical compositions.. .
09/25/14
20140288149
 Mir-142 and antagonists thereof for treating disease patent thumbnailnew patent Mir-142 and antagonists thereof for treating disease
Methods of treating various conditions using mir-142, mir-142 mimics, and antagonists of mir-142 are provided.. .
09/25/14
20140288139
 Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence patent thumbnailnew patent Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
Compositions and methods are provided that are useful for diagnosing, treating, and monitoring alcohol dependence and disorders, susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders. The methods include treating patients with an antagonist of the serotonin receptor 5-ht3 for such disorders, wherein the patient's serotonin transporter gene slc6a4 is known to have particular genotypes..
09/25/14
20140288138
 Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats patent thumbnailnew patent Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats
A method is described for the treatment of systemic diseases in cats. A composition is administered to a cat, where the composition includes a therapeutically effective amount of angiotensin ii receptor 1 (at-1) antagonist (sartan)..
09/25/14
20140288112
 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists patent thumbnailnew patent 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
Wherein r1, r2, r3, a, and g are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds..
09/25/14
20140288106
 Cycloalkane carboxylic acid derivatives as cxcr3 receptor antagonists patent thumbnailnew patent Cycloalkane carboxylic acid derivatives as cxcr3 receptor antagonists
That are useful for the preventive or therapeutic treatment of diseases caused by abnormal activation of cxcr3 chemokines. The invention relates furthermore to a process for the preparation of said compounds, to pharmaceutical compositions containing said compounds and to novel intermediates used in the preparation of said compounds..
09/25/14
20140288096
 P13 kinase antagonists patent thumbnailnew patent P13 kinase antagonists
The present invention provides novel pi3-kinase antagonists and methods of use thereof.. .
09/25/14
20140288057
 Method and composition for treating alzheimer-type dementia patent thumbnailnew patent Method and composition for treating alzheimer-type dementia
There is described a method for increasing the maximal tolerated dose and thus the efficacy of an acetylcholinesterase inhibitor (achei) in a patient suffering from an alzheimer type dementia by decreasing concomitant adverse effects by administration of said achei in combination with a non-anticholinergic antiemetic agent, whereby an enhanced acetylcholinesterase inhibition in the cns of said patient is achieved and alleviation of the symptoms of alzheimer type dementia in said patient is thereby improved to a greater extent. The use of a non-anticholinergic antiemetic agent for the preparation of a pharmaceutical composition for the treatment of alzheimer type dementia in combination with an acetylcholinesterase inhibitor (achei) and pharmaceutical compositions comprising (a) a 5ht3 receptor antagonist, a dopamine antagonist, a h1-receptor antagonist, a cannabinoid agonist, aprepitant or casopitant as an antiemetic agent and (b) an acetylcholinesterase inhibitor are also described..
09/25/14
20140288036
 Novel c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity patent thumbnailnew patent Novel c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity
Described are steroidal c-17 benzoazoles, pyrimidinoazoles (azabenzoazoles) and diazines. Methods for their synthesis are also described, which include methods having a step of nucleophilic vinylic “addition-elimination” substitution reaction of 3β-acetoxy-17-chloro-16-formylandrosta-5,16-diene or analogs thereof and benzoazole or pyrimidinoazole nucleophiles and methods having a palladium catalyzed cross-coupling reaction of 17-iodoandrosta-5,16-dien-3β-ol or analogs thereof with tributylstannyl diazines.
09/25/14
20140286965
new patent Ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis
The present invention relates to uses, methods and compositions for treating crescentic glomerulonephritis. More specifically, the present invention relates to a ddr1 antagonist or an inhibitor of ddr1 gene expression for the prevention or the treatment of said disease..
09/25/14
20140286953
new patent Hepcidin, hepcidin antagonists and methods of use
The invention relates to purified, correctly folded hepcidin, antibodies that bind hepcidin, and methods of making and using such materials. Also provide are methods of treated hepcidin-related disorders..
09/25/14
20140286936
new patent Anti-human cxcr4 antibodies
The present invention provides novel antibodies to human cxcr4 with high affinity to the target and the ability to act potently as antagonists. The antibodies disclosed herein bind to a diverse range of epitopes..
09/18/14
20140275497
Methods for making cytokine compositions from tissues using non-centrifugal methods
Apparatus and methods for generating a solution rich in interleukin-1 receptor antagonist from a tissue comprising cytokine-producing cells. The apparatus can include a filter used with a separation system.
09/18/14
20140275232
Small molecule antagonists of bacterial quorum-sensing receptors
A novel small molecule antagonizes two types of acyl homoserine lactone receptors: membrane-bound and cytoplasmic. A focused library of analogs and derivatives of the original antagonist was synthesized.
09/18/14
20140275142
Combinations of opioid/tlr4 antagonist and a cyclooxygenase (cox) inhibitor for use in the treatment of pain
Disclosed are compositions for treatment of pain comprising a first compound and a second compound, the first compound is an opioid antagonist that treats pain by blocking toll-like receptor 4 (tlr4) and the second compound is a cyclooxygenase (cox) inhibitor that enhances the pain treatment effect of the first compound. Examples of opioid antagonist include naltrexone and naloxone.
09/18/14
20140275141
Combinations of opioid/tlr4 antagonists and acetyl-para-aminophenol (apap) for use in the treatment of pain
Disclosed are compositions for the treatment of pain comprising a first compound and a second compound, the first compound is an opioid antagonist that treats pain by blocking toll-like receptor 4 (tlr4) and the second compound is acetyl-para-aminophenol (apap) that enhances the pain treatment effect of the first compound. Examples of opioid antagonist include naltrexone and naloxone, synergistic pharmaceutical compositions thereof, and their use in the treatment, prevention, and reversal of neuropathic and nociceptive pain..
09/18/14
20140275133
Mineralocorticoid receptor antagonists
The present invention is directed to compounds of the formula (i) as well as pharmaceutically acceptable salts thereof that are possible useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the formula (i), to their possible use for the treatment of the above mentioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the formula (i)..
09/18/14
20140275116
Product and method for treating diarrhea
A method of treating diarrhea in a patient includes administering an h1 receptor antagonist and an h2 receptor antagonist to the patient.. .
09/18/14
20140275105
Crystal of androgen receptor antagonistic compound
[solution] a01-type crystal of monohydrate, a01-type crystal of hydrochloride, a01-type crystal of hydrobromide, and a01-type crystal of methanesulfonate of (2r,5s)-4-(3-chloro-4-cyanophenyl)-n-(2-cyclopropylpyrimidin-5-yl)-2,5-dimethylpiperazine-1-carboxamide, which have certain crystal forms, are provided.. .
09/18/14
20140275102
Solid state forms of 6-[4-[3-((r)-2-methylpyrrolidine-1-yl)-propoxy]phenyl] 2h-pyridazine-3-one hydrochloride
Solid state forms of the compound 6-[4-[3-((r)-2-methylpyrrolidine-1-yl)-propoxy]phenyl]2h-pyridazine-3-one hydrochloride (compound 1), processes for preparing the solid state forms, and pharmaceutical compositions thereof, are provided. Compound 1 is a histamine h3 receptor antagonist/inverse agonist.
09/18/14
20140275097
Novel chiral n-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor mediated disorders and chiral synthesis thereof
The present invention relates to novel compounds of formula i and their use in therapeutic treatments. The invention further relates to a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using n-sp3 protective groups.
09/18/14
20140275074
Heterocyclic derivative having pgd2 receptor antagonist activity
Wherein x1, x2, x3, x4, x5, r5, r6, r7, r8, n, p, q, ring a and ring b are as described in the specification, or a pharmaceutically acceptable salt thereof.. .
09/18/14
20140275050
2,5-disubstituted thiomorpholine orexin receptor antagonists
The present invention is directed to 2,5-disubstituted thiomorpholine amide compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2,5-disubstituted thiomorpholine amide compounds described herein in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
09/18/14
20140275049
Substituted pyrazole analogs as rar antagonists
The present invention provides compounds of formula i or a pharmaceutical salt thereof; methods of treating osteoarthritis and the pain associated with osteoarthritis using the compounds; and processes for preparing the compounds.. .
09/18/14
20140275017
Cgrp receptor antagonists
(wherein variables a1, a2, a3, ring-b, m, n, j, e1, e2, e3, r5, rpg and y are as described herein), which are useful as antagonists of cgrp receptors, and useful in the treatment or prevention of diseases in which cgrp receptors are involved, such as headache, and in particular migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising the compounds of formula (i) and the use of these compounds and compositions in the prevention or treatment of diseases in which cgrp receptors are involved..
09/18/14
20140275006
Azole derivative
Specifically, the invention provides azole derivatives represented by general formula (i), or pharmaceutically acceptable salts thereof that have an antagonistic action against the arginine-vasopressin (avp) v1b receptor:. .
09/18/14
20140274983
Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
Prodrugs of steroidal c-17 benzoazoles, pyrimidinoazoles (az-abenzoazoles) and diazines. Methods of synthesis are also described, whereby a prodrug group is substituted for a functional group at a ring portion of the abc ring structure of the steroid.
09/18/14
20140274900
Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
The invention relates to methods for treating stress sensitive condition. For instance a subject having or at risk of having a stress-sensitive condition may be treated with a growth hormone (gh) antagonist in an effective amount to treat the stress sensitive condition.
09/18/14
20140274895
Methods and non-immunogenic compositions for treating inflammatory disorders
Methods for making non-immunogenic anti-inflammatory cytokine compositions, comprising (a) obtaining a liquid comprising cytokine producing cells from a mammalian donor; (b) contacting the liquid with a solid extraction material to generate a composition rich in interleukin-1 receptor antagonist; and performing one or both of (i) removing cells from the composition and (ii) freezing the composition. The compositions comprise two or more of il1-ra, stnf-r1, stnf-rii, igf-i, egf, hgf, pdgf-ab, pdgf-bb, vegf, tgf-β1, and sil-1rii, compositions may also contain white blood cells and platelets..
09/18/14
20140274894
Methods for making cytokine compositions from tissues using non-centrifugal methods
Non-centrifugal methods for generating a solution rich in interleukin-1 receptor antagonist from a tissue comprising cytokine-producing cells. The solution rich in il-1ra can also include at least one of stnf-ri, stnf-rii, igf-i, egf, hgf, pdgf-ab, pdgf-bb, vegf, tgf-β1, and sil-1 rii..
09/18/14
20140271677
Newcastle disease viruses and uses thereof
Described herein are chimeric newcastle disease viruses engineered to express an agonist of a co-stimulatory signal of an immune cell and compositions comprising such viruses. Also described herein are chimeric newcastle disease viruses engineered to express an antagonist of an inhibitory signal of an immune cell and compositions comprising such viruses.
09/18/14
20140271673
Use of lxr antagonists for treatment of side effects of elevated glucocorticoid levels
The present application is directed to uses of an agent that antagonizes the lxrβ receptor for the treatment of side effects associated with elevated glucocorticoid levels as well as uses of a glucocorticoid in combination with the agent that antagonizes the lxrβ receptor for treatment of a disease wherein glucocorticoid treatment is indicated.. .
09/18/14
20140271648
Interferon alpha and omega antibody antagonists
Broadly neutralizing interferon-α and interferon-ω antibody antagonists, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing are useful in the treatment of diseases associated with increased production of ifnα and ifnω.. .
09/18/14
20140271645
Method for treating inflammation
A method for treating il-20 induced inflammation. An antagonist to il-20 is administered to treat inflammation and associated diseases.
09/18/14
20140271642
Il-33 antagonists and uses thereof
The present invention provides interleukin-33 (il-33) antagonists comprising one or more il-33-binding domains and one or more multimerizing domains and methods of using the same. According to certain embodiments of the invention, the il-33-binding domains can comprise an il-33-binding portion of an st2 protein and/or an extracellular portion of an il-1 racp protein.
09/18/14
20140271606
Methods of using adenosine receptor antagonists for treating bleeding disorders
Methods of treating bleeding disorders, such as bleeding diseases such as hemophilia, by administering adenosine 2a receptor and/or adenosine 2b receptor antagonists to subjects in need thereof are disclosed. In some embodiments, the methods further include administration of the antagonist with one or more of factor viii, factor ix and factor xi to treat the bleeding disorder..
09/11/14
20140256780
Pyrazole derivatives as modulators of hepatocyte growth factor (scatter factor) activity
And pharmaceutically acceptable derivatives thereof, wherein r1, r2 and b are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases in which hgf/sf or the activities thereof, or agonists or antagonists thereof have a therapeutically useful role.. .
09/11/14
20140256764
Tamper resistant dosage form comprising an adsorbent and an adverse agent
Pharmaceutical compositions and dosage forms comprising an adsorbent, and an adverse agent, such as an opioid antagonist. In one embodiment, at least a portion of the adverse agent is on the surface or within the micropore structure of an adsorbent material.
09/11/14
20140256744
Polycyclic compounds as lysophosphatidic acid receptor antagonists
Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating lpa-dependent or lpa-mediated conditions or diseases..
09/11/14
20140256727
Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity
The present invention provides compositions and formulations of compounds having formula (i) and pharmaceutically acceptable derivatives thereof, wherein p, r1, r2 and b are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of injuries, conditions or diseases in which hgf/sf or the activities thereof, or agonists or antagonists thereof have a therapeutically useful role. In addition, methods are provided for treating such diseases or diseases starting at a time after the onset of the injury, condition or disease..
09/11/14
20140256725
Fsh receptor antagonists
The invention relates to fsh receptor antagonist according to general formula i or a pharmaceutically acceptable salt thereof and to a pharmaceutical composition containing the same. The compounds can be used for the treatment and prevention of endometriosis, for the treatment and prevention of pre-menopausal and peri-menopausal hormone-dependent breast cancer, for contraception, and for the treatment of uterine fibroids and other menstrual-related disorders..
09/11/14
20140256723
Mineralocorticoid receptor antagonists
The present invention is directed to compounds of the formula (i) as well as pharmaceutically acceptable salts thereof that are aldosterone receptor antagonists which might be useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the formula (i), to their possible use for the treatment of the above-mentioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the formula (i)..
09/11/14
20140256720
Cancer treatment using bmp inhibitor
Methods for regulating cancer cell growth and survival, inhibiting cancer cell growth, promoting cancer cell death, and/or treating a cancer make use of antagonists of a type i bmp receptor. In some embodiments the cancer is a lung cancer and the cancer cell is a lung cancer cell..
09/11/14
20140256652
Polypeptides involved in immune response
Novel polypeptides which comprise a receptor-ligand pair involved in t-cell activation are disclosed. Nucleic acid molecules encoding said polypeptides, and vectors and host cells for expressing same are also disclosed.
09/11/14
20140256004
Process for the preparation of an endothelin receptor antagonist
The present invention relates to a novel process for the preparation of a compound of formula (i) wherein r is a methyl or methoxy group; to certain novel intermediates prepared in such a process and their use.. .
09/11/14
20140255491
Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
Inhalation solutions for administration of muscarinic antagonists for the treatment of breathing disorders, such as copd, are provided.. .
09/11/14
20140255429
Methods of treating autoimmune diseases with dll4 antagonists
The present invention provides methods of treating a disease or disorder, in which increasing the number of regulatory t cell (treg) is beneficial, by administering to a subject suffering from such a disease or disorder a therapeutically effective amount of dll4 antagonists that block dll4-notch signal pathways, thereby increasing the number of treg. Diseases or disorders treatable by the methods of the invention include autoimmune diseases or disorders, such as multiple sclerosis (ms), diabetes, and the like.
09/11/14
20140255413
Combination therapy for neoplasia treatment
The present invention relates to an insulin-like growth factor (igf) receptor antagonist for use in the treatment of prostate neoplasia, including benign prostatic hyperplasia (bph), prostate cancer, and particularly crpc, wherein the antagonist is used in combination with an androgen receptor antagonist. An embodiment of the invention is where the androgen receptor antagonist is enzalutamide..
09/11/14
20140255403
Oral composition comprising a tnf antagonist and use thereof
This application further describes a method of treating, preventing or reducing the severity of obesity, the method comprising, administering to the subject a therapeutically effective amount of a tnf antagonist molecule.. .
09/11/14
20140255401
Kv1.3 antagonists and methods of use
The present invention relates to kv1.3 antagonists, and polynucleotides encoding them, and methods of making and using the foregoing.. .
09/11/14
20140255397
Methods and compositions for modulation of blood-neural barrier
Methods and compositions for modulating blood-neural barrier (bnb) for the treatment of cns conditions such as edema, and for increased drug delivery efficacy across the bnb. The present invention further relates to improved tpa treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the pdgf signaling pathway.
09/11/14
20140255390
Method of treating rheumatoid arthritis with an anti-il-6r antibody
The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hil-6r). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (nsaid), a glucocorticoid, a disease-modifying anti-rheumatic drug (dmard), or a tnf-alpha antagonist, t-cell blocker, anti-cd20 antibody, an il-1, jak or il-17 antagonist, or any combination thereof..
09/11/14
20140255388
Toll like receptor 3 antagonists, methods and uses
Toll like receptor 3 (tlr3) antagonists, polynucleotides encoding tlr3 antagonists or fragments, and methods of making and using the foregoing are disclosed.. .
09/11/14
20140255386
Microrna modulators and method for identifying and using the same
The present invention is a method for identifying agents which modulate microrna activity. The invention involves contacting a cell harboring a microrna and a microrna binding sequence, which is operably linked to a nucleic acid molecule encoding a reporter protein, with a test agent and determining whether the test agent increases or decreases the expression of the reporter protein thereby identifying a microrna modulator.


Popular terms: [SEARCH]

Antagonist topics: Antagonist, Recurrence, Proliferative Disorder, Proliferative, Antibodies, Progesterone, Dicyclomine, Scopolamine, Extracellular, Pharmaceutically Acceptable Salt, Metalloprotein, Nucleic Acids, Polynucleotide, Nucleic Acid, Monoclonal

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Antagonist for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Antagonist with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.3986

3453

72 - 0 - 73